In the wound care world, January 1, 2025 is now known as "Black Wednesday." CMS's 2025 Outpatient Prospective Payment System (OPPS) final rule implemented changes that effectively collapsed reimbursement for skin substitutes in the hospital outpatient setting—a move that sent shockwaves through a $19.6 billion market.
For investors with exposure to wound care companies, understanding what happened and what comes next is critical.
What CMS Actually Changed
The changes were technical but devastating. CMS restructured how skin substitutes are categorized and reimbursed under OPPS, creating three new tiers based on FDA regulatory classification:
| New Category | Products | 2024 Payment | 2025 Payment | Impact |
|---|---|---|---|---|
| High-cost Category (Cellular/tissue-based) | Apligraf, Dermagraft, etc. | $1,500-$4,000/cm² | $1,200-$1,800/cm² | -25% to -55% |
| Low-cost Category (Acellular matrices) | Most synthetic/acellular products | $800-$2,000/cm² | $200-$400/cm² | -75% to -90% |
| Packaged (Included in procedure) | Lowest-cost products | Separate payment | $0 (packaged) | -100% |
The Rationale
CMS justified these changes based on several factors:
- Cost growth: Skin substitute spending under Medicare Part B grew from $1.2B in 2017 to over $4B in 2023
- Utilization concerns: OIG reports flagged questionable utilization patterns, particularly in diabetic foot ulcers
- Evidence gaps: Many products lack robust comparative effectiveness data
- Market distortions: High ASP (Average Sales Price) reimbursement was encouraging premium pricing
Clinical Reality Check
As a physician, I understand the policy intent—wound care has had utilization issues. But the blunt instrument of reimbursement cuts doesn't distinguish between appropriate and inappropriate use. Diabetic patients with genuine healing deficits will have reduced access to effective therapies.
Market Impact Assessment
Companies Most Affected
The impact varies significantly by company and product portfolio:
- Organogenesis (Apligraf, Dermagraft): Moderate impact—products in higher-cost tier, but still facing significant cuts
- Smith+Nephew (Grafix, Stravix): Significant exposure to wound care segment under pressure
- MiMedx (EpiFix, AmnioFix): Severe impact—amniotic tissue products disproportionately affected
- Integra LifeSciences: Moderate—diversified portfolio provides some insulation
- Smaller pure-play wound care companies: Existential threat for some
Private Equity Exposure
Several PE-backed wound care platforms are facing serious challenges:
- Roll-up strategies predicated on high-margin wound care products
- Debt structures sized to historical cash flows now at risk
- Exit timelines potentially extended by 2-3+ years
- Some portfolio companies may require additional capital or restructuring
Investment Due Diligence Question
For any wound care investment, ask: "What percentage of revenue comes from hospital outpatient skin substitute application, and what's the payer-setting breakdown?" Companies with >40% exposure to Medicare HOPD are at highest risk.
Strategic Responses We're Seeing
1. Site-of-Service Shift
Companies are aggressively moving procedures from hospital outpatient to:
- Physician offices: MPFS (Medicare Physician Fee Schedule) rates less affected
- Ambulatory Surgery Centers: Different payment methodology
- Hospital outpatient-to-physician office service agreements: Complex arrangements to shift billing
2. Product Reformulation
Some companies are exploring whether product modifications could achieve higher-tier classification:
- Adding cellular components to acellular products
- Pursuing FDA reclassification for existing products
- Developing next-generation products designed for higher tiers
3. Evidence Generation
Companies with robust clinical data are better positioned to:
- Negotiate with commercial payers who may not follow CMS
- Support appeals and coverage determinations
- Differentiate from commoditized competitors
4. International Expansion
Companies are accelerating non-US market development where reimbursement may be more favorable, particularly in EU markets with established wound care protocols.
What Comes Next
Near-Term (2026)
- Industry lobbying for legislative fix (unlikely to succeed quickly)
- CMS clarifications on product categorization (ongoing)
- Potential CMS reconsideration for 2027 OPPS cycle
- Market consolidation as weaker players exit
Medium-Term (2027-2028)
- New product development cycles complete—expect "category-optimized" products
- Site-of-service shifts fully implemented
- Potential for new coverage policies distinguishing evidence-based products
- M&A activity as larger players acquire distressed assets
Long-Term Implications
The skin substitute situation illustrates a broader CMS trend: aggressive cost containment in categories with rapid spending growth and limited comparative effectiveness evidence. Similar dynamics exist in:
- Cardiac monitoring devices
- Diabetes technology (CGM, insulin pumps)
- Orthopedic biologics
- Regenerative medicine broadly
Investment Thesis Evolution
The wound care market isn't dead—it's being restructured. Winners will be companies with genuine clinical differentiation, robust evidence, and diversified payer/setting exposure. Pure pricing power without clinical evidence is no longer a viable strategy.
Questions Investors Should Ask
When evaluating wound care investments in this environment:
- What is the Medicare HOPD revenue exposure, and how is it trending?
- What clinical evidence exists differentiating this product from lower-cost alternatives?
- What is the company's site-of-service diversification strategy?
- How dependent is the business model on ASP-based reimbursement vs. contracted rates?
- What is the FDA regulatory classification, and could products be reclassified?
- What does the balance sheet look like—can the company weather 2-3 years of transition?
References
- CMS. "CMS Modernizes Payment Accuracy and Significantly Cuts Spending Waste." October 2025. cms.gov
- HCH Lawyers. "CMS Reclassifies Skin Substitutes for 2026: Key Changes." December 2025. hchlawyers.com
- Reed Smith. "CMS reclassifies certain skin substitutes and dramatically cuts payment under Medicare Part B." October 2025. reedsmith.com
- Applied Policy. "Skin Substitutes in Medicare: Trends, Challenges, and CMS's Policy Response." appliedpolicy.com
- Wound Care Alliance. "Medicare's 2026 Rule Shakes Up Wound Care Payments — What You Need to Know." thewca.com
- CMS. "Final Local Coverage Determinations (LCDs) for Certain Skin Substitutes Withdrawn." December 2025. cms.gov
Want Deeper Analysis for Your Portfolio?
Our proprietary risk framework has been validated against documented medical device companies. Get a complimentary risk pattern analysis for your medtech investments.